Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,689 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal saline solution Clear all
Completed Not applicable Interventional

Use of Salt-Water Solution to Improve Symptoms in Concussion

NCT00142090
View directory record Official record
Conditions
Brain Concussion, Post-Concussion Symptoms
Interventions
3% Hypertonic saline, Placebo
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
6 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

NCT02377414
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban solution for Infusion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

NCT00738699
View directory record Official record
Conditions
Ovarian Cancer
Interventions
MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial

NCT06920264
View directory record Official record
Conditions
This Study Will Evaluate Whether TXA Reduces Pain
Interventions
Tranexamic acid, placebo
Drug · Other
Lead sponsor
St. Louis Joint Replacement Institute
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bridgeton, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
View directory record Official record
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 21, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

NCT00427609
View directory record Official record
Conditions
Psoriasis
Interventions
Bicillin L-A
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 21, 2026, 7:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

NCT03705234
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
University of Oxford
Other
Eligibility
40 Years and older
Enrollment
16,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2049
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AB103 Peptide Antagonist in Healthy Volunteers

NCT01166984
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
AB103, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

NCT05881993
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
CBP-4888, Placebo
Drug · Other
Lead sponsor
Comanche Biopharma
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 21, 2026, 7:32 PM EDT
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 21, 2026, 7:32 PM EDT
Withdrawn Phase 3 Interventional

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

NCT03749096
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Intravenous Immunoglobulins, Human, Placebos
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 21, 2026, 7:32 PM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

NCT07621796
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous tenecteplase (TNK), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Recruiting Phase 3 Interventional

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
45
States / cities
La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Comparing the Effects of Lactated Ringers and Normal Saline in Acute Pancreatitis

NCT03242473
View directory record Official record
Conditions
Pancreatitis
Interventions
Fluid Management
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 18 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

NCT01663103
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Intravenous Tranexamic Acid During Rhytidectomy

NCT03970213
View directory record Official record
Conditions
Bleeding, Bruising Face, Swelling Lips & Face
Interventions
Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Glasgold Group Plastic Surgery
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

NCT02760069
View directory record Official record
Conditions
Nausea
Interventions
Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 7:32 PM EDT
Terminated Phase 4 Interventional

Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study

NCT00771862
View directory record Official record
Conditions
Amputation, Phantom Limb Pain, Stump Pain
Interventions
perineural ropivicaine
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 21, 2026, 7:32 PM EDT